Skip to main content

LGND Ligand Pharmaceuticals Incorporated

Healthcare

strong quality, premium valuation.

Quality
Top tier
Valuation
Expensive
Key signals
Top-quintile 6-month momentum Filed revenue acceleration
302.74
302.74 Close (USD) Loading candles…

Is Ligand Pharmaceuticals Incorporated a buy? Fundamentals and valuation first

  • Quality is top-tier. Operating margin ranks above roughly 86% of the liquid US common-stock universe. TTM ROE is about 20.4%.

  • Valuation is expensive. TTM P/E is in the 84th percentile, above most peers.

  • Recent volatility is moderate. 60-day annualized volatility is near the 33th percentile. Average 20-day dollar volume is about $79.0M.

  • Signals are active now. Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Ligand Pharmaceuticals Incorporated to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 88.41567291311755%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

26 historical occurrences (since 2016-07-06)
Average forward return after Top-quintile 6-month momentum。20-day: Win 44%, Sample 25, Median -1.9%, Excess -3.01%, Beat mkt rate 40%；60-day: Win 56%, Sample 25, Median +3.37%, Excess -3.06%, Beat mkt rate 52%；120-day: Win 50%, Sample 24, Median +2.42%, Excess -2.19%, Beat mkt rate 54.2%

120 days after: historical avg +3.53%

20-day -3.03%
60-day -0.23%
120-day +3.53%
20-day
60-day
120-day
Win
44%
56%
50%
Sample
25
25
24
Median
-1.9%
+3.37%
+2.42%
Excess
-3.01%
-3.06%
-2.19%
Beat mkt rate
40%
52%
54.2%

Over 24 occurrences, 120-day forward avg gained 3.53%, lagged the market by 2.19 pts; win rate 50%.

Filed revenue acceleration

Active · now 54.88634425110883%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

10 historical occurrences (since 2018-05-09)
Average forward return after Filed revenue acceleration。20-day: Win 40%, Sample 10, Median -2.4%, Excess +0.11%, Beat mkt rate 30%；60-day: Win 33.3%, Sample 9, Median -5.33%, Excess -1.9%, Beat mkt rate 33.3%；120-day: Win 55.6%, Sample 9, Median +5.98%, Excess +0.04%, Beat mkt rate 66.7%

120 days after: historical avg +4.9%

20-day +0.89%
60-day +1.3%
120-day +4.9%
20-day
60-day
120-day
Win
40%
33.3%
55.6%
Sample
10
9
9
Median
-2.4%
-5.33%
+5.98%
Excess
+0.11%
-1.9%
+0.04%
Beat mkt rate
30%
33.3%
66.7%

Over 9 occurrences, 120-day forward avg gained 4.9%, beat the market by 0.04 pts; win rate 55.6%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 7Insufficient data
20-40 You are here103+132.3% +133% 100% +104.8%
40-60 378+35.8% +34.7% 50.3% +22.6%
60-80 155+16.3% -0.6% 49% -8.6%
80-100 55+59.6% +56.1% 100% +35.8%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 32.38, placing it in the 35.8 own-history percentile, inside the 20-40 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+32.7%
Win rate 100% Excess +23%
83d
+28.3%
Win rate 64.3% Excess +21.8%
252d
+16.4%
Win rate 75% Excess +7.5%
152d
60-day momentum down
Insufficient data
(19d)
Now
+4.7%
Win rate 59% Excess -1.1%
212d
+1.6%
Win rate 37% Excess -11%
100d

Currently in “Middle × 60-day momentum down”: across 212 historical days, 120-day forward avg gained 4.7%, win rate 59%, lagged the market by 1.1%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,357 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.05%, a 57.7% positive-return rate, and +2.70 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 times historically; 60-day forward avg +9.16%, win rate 72.2%, beating the market by +3.94 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

32 times historically; 60-day forward avg +3.28%, win rate 57.1%, beating the market by -0.8 pts on average.

Continue researching Ligand Pharmaceuticals Incorporated with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.